Anticonvulsant-induced dyskinesia

Expert Opinion on Drug Safety

Volumn 2, Issue 4, 2003, Pages 385-393

  Zaatreh, Megdad M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

adverse effects; anticonvulsants; dyskinesia; epilepsy; movement disorders

Indexed keywords

ANTICONVULSIVE AGENT;

DYSKINESIA; HUMAN; REVIEW; RISK FACTOR;

ANTICONVULSANTS; DYSKINESIA, DRUG-INDUCED; HUMANS; RISK FACTORS;

EID: 0141483639     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2.4.385     Document Type: Review

References (83)

1. HARRISON MB, LYONS GR, LANDOW ER: Phenytoin and dyskinesias: a report of two cases and review of the literature. Mov. Disord. (1993) 8(1):19-27. (Pubitemid 23039225)
2. RASMUSSEN S, KRISTENSEN M: Choreoathetosis during phenytoin treatment. Acta Med. Scand. (1977) 201(3):239-241. (Pubitemid 8057734)
3. WIZNITZER M, YOUNKIN D: Phenobarbital-induced dyskinesia in a neurologically-impaired child. Neurology (1984) 34(12):1600-1601. (Pubitemid 15220510)
4. YOSHIDA M, YAMADA S, OZAKI Y, NAKANISHI T: Phenytoin-induced orofacial dyskinesia. A case report. J. Neurol. (1985) 231(6):340-342. (Pubitemid 15197064)
5. KOUKKARI MW, VANEFSKY MA, STEINBERG GK, HAHN JS: Phenytoin-related chorea in children with deep hemispheric vascular malformations. J. Child Neurol. (1996) 11(6):490-491. (Pubitemid 26412206)
6. MONTENEGRO MA, SCOTONI AE, CENDES F: Dyskinesia induced by phenytoin. Arq. Neuropsiquiatr. (1999) 57(2B):356-360. (Pubitemid 29295619)
7. ZAATREH M, TENNISON M, D'CRUZ O, BEACH RL: Anticonvulsants-induced chorea: a role for pharmacodynamic drug interaction? Seizure (2001) 10(8):596-599. (Pubitemid 34083173)
8. LUHDORF K, LUND M: Phenytoin-induced hyperkinesia. Epilepsia (1977) 18:409-415.
9. CHALHUB EG, DE VIVO DC: Phenytoin-induced choreoathetosis. J. Pediatr. (1976) 89:153-165.
10. HOWRIE DL, CRUMRINE PK : Phenytoin-induced movement disorder associated with intravenous administration for status epilepticus. Clin. Pediatr. (1985) 24(8):467-469. (Pubitemid 15240369)
11. CHAUDHARY N, RAVAT SH, SHAH PU: Phenytoin-induced dyskinesia. Indian Pediatr. (1998) 35(3):274-276.
12. KURLAN R, KERSUN J, BEHR J et al.: Carbamazepine-induced tics. Clin. Neuropharmacol. (1989) 12(4):298-302. (Pubitemid 19273665)
13. LOMBROSO CT: Lamotrigine-induced tourettism. Neurology (1999) 52:1191-1194. (Pubitemid 29177920)
14. SOTERO DE MENEZES MA, RHO JM, MURPHY P, CHEYETTE S: Lamotrigine-induced tic disorder: report of five pediatric cases. Epilepsia (2000) 41(7):862-867. (Pubitemid 30439578)
15. BURD L, KERBESHIAN J, FISHER W, GASCON G: Anticonvulsant medications: an iatrogenic cause of tic disorders. Can. J. Psychiatry (1986) 31(5):419-423. (Pubitemid 16092259)
16. NAUSIEDA PA, KOLLER WC, KLAWANS HL, WEINER WJ: Phenytoin and choreic movements. N. Engl. J. Med. (1978) 11(298):1093-1094. (Pubitemid 8362304)
17. LIGHTMAN SL: Phenobarbital dyskinesia. Postgrad. Med. J. (1978) 54(628):114-115. (Pubitemid 8276967)
18. CHUDNOW RS, DEWEY RB, LAWSON CR: Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients. Arch. Neurol. (1997) 54(7):910-912. (Pubitemid 27306630)
19. NORTON JW, QUARLES E: Gabapentin-related dyskinesia. J. Clin. Psychopharmacol. (2001) 21(6):623-624.
20. SCHWARTZMAN MJ, LEPPIK IE: Carbamazepine-induced dyskinesia and ophthalmoplegia. Cleve. Clin. J. Med. (1990) 57(4):367-372. (Pubitemid 20320142)
21. MURPHY MJ, GOLDSTEIN MN: Diphenylhydantoin-induced asterixis. A clinical study. JAMA (1974) 29(229):538-540.
22. CHI WM, CHUA KS, KONG KH: Phenytoin-induced asterixis-uncommon or under-diagnosed? Brain Inj. (2000) 14(9):847-850.
23. SHULMAN LM, SINGER C, WEINER WJ: Phenytoin-induced focal chorea. Mov. Disord. (1996) 11(1):111-114.
24. DUARTE J, SEMPERE AP, CABEZAS MC, MARCOS J, CLAVERIA LE: Postural myoclonus induced by phenytoin. Clin. Neuropharmacol. (1996) 19(6):536-538. (Pubitemid 26391360)
25. SECHI GP, PIRAS MR, ROSATI G et al.: Phenobarbital-induced buccolingual dyskinesia in oral apraxia. Eur. Neurol. (1988) 28(3):139-141.
26. PETERS HA: Anticonvulsant drug intolerance. Neurology (1962) 12:299.
27. FILLOUX F, THOMPSON JA: Transient chorea induced by phenytoin. J. Pediatr. (1987) 110:639-641. (Pubitemid 17049062)
28. TURKDOGAN D, ONAT F, TURE U, PAMIR N: Phenytoin toxicity with mandibular tremor secondary to intravenous administration. Int. J. Clin. Pharmacol. Ther. (2002) 40(1):18-19. (Pubitemid 34100790)
29. MOSS W, OJUKWU C, CHIRIBOGA CA: Phenytoin-induced movement disorder. Unilateral presentation in a child and response to diphenhydramine. Clin. Pediatr. (1994) 33(10):634-638.
30. GONI M, JIMENEZ M, FEIJOO M: Parkinsonism induced by phenytoin. Clin. Neuropharmacol. (1985) 8(4):383-384. (Pubitemid 16175348)
31. PRENSKY AL, DEVIVO DC, PALKES H: Severe bradykinesia as a manifestation of toxicity to antiepileptic medications. J. Pediatr. (1971) 78(4):700-704.
32. HOLTMANN M, KORN-MERKER E, BOENIGK HE: Carbamazepine-induced combined phonic and motor tic in a boy with Down's syndrome. Epileptic Disord. (2000) 2(1):39-40. (Pubitemid 30226347)
33. AGUGLIA U, ZAPPIA M, QUATTRONE A: Carbamazepine-induced nonepileptic myoclonus in a child with benign epilepsy. Epilepsia (1987) 28(5):515-518. (Pubitemid 17146599)
34. AMBROSETTO G, RIVA R, BARUZZI A: Hyperammonemia in asterixis induced by carbamazepine: two case reports. Acta Neurol. Scand. (1984) 69(3):186-189. (Pubitemid 14155923)
35. RITTMANNSBERGER H, LEBLHUBER F: Asterixis induced by carbamazepine therapy. Biol. Psychiatry (1992) 32(4):364-368.
36. GIGLI GL, SCALISE A, SILVESTRI G et al.: Clinical case report: multiple idiosyncratic adverse effects of antiepileptic drugs in trisomy 9p. Int. J. Neurosci. (1996) 87(3-4):181-189.
37. CROSLEY CJ, SWENDER PT: Dystonia associated with carbamazepine administration: experience in brain-damaged children. Pediatrics (1979) 63(4):612-615. (Pubitemid 9125476)
38. STRYJER R, STROUS RD, BAR F, ULMAN AM, RABEY JM: Segmental dystonia as the sole manifestation of carbamazepine toxicity. Gen. Hosp. Psychiatry (2002) 24(2):114-115. (Pubitemid 34175133)
39. BIMPONG-BUTA K, FROESCHER W: Carbamazepine-induced choreoathetoid dyskinesias. J. Neurol. Neurosurg. Psychiatry (1982) 45:560. (Pubitemid 12070647)
40. JOYCE RP, GUNDERSON CH: Carbamazepine-induced orofacial dyskinesia. Neurology (1980) 30(12):1333-1334. (Pubitemid 11209191)
41. JACOME D: Movement disorder induced by carbamazepine. Neurology (1981) 31(8):1059-1060.
42. WEAVER DF, CAMFIELD P, FRASER A: Massive carbamazepine overdose: clinical and pharmacologic observations in five episodes. Neurology (1988) 38(5):755-759.
43. GUNAL DI, GULERYUZ M, BINGOL CA: Reversible valproate-induced choreiform movements. Seizure (2002) 11(3):205-206. (Pubitemid 34693053)
44. LANCMAN ME, ASCONAPE JJ, PENRY JK: Choreiform movements associated with the use of valproate. Arch. Neurol. (1994) 51:702-704. (Pubitemid 24201890)
45. KLAWANS HL, CARVEY PM, TANNER CM: Drug induced myoclonus. Adv. Neurol. (1986) 43:251-261.
46. ONOFRJ M, THOMAS A, PACI C: Reversible parkinsonism induced by prolonged treatment with valproate. J. Neurol. (1998) 245(12):794-796. (Pubitemid 28505274)
47. ARMON C, SHIN C, MILLER P et al.: Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology (1996) 47(3):626-635. (Pubitemid 26307288)
48. SASSO E, DELSOLDATO S, NEGROTTI A, MANCIA D: Reversible valproate-induced extrapyramidal disorders. Epilepsia (1994) 35(2):391-393 (Pubitemid 24138827)
49. ALVAREZ-GOMEZ MJ, VAAMONDE J, NARBONA J et al.: Parkinsonian syndrome in childhood after sodium valproate administration. Clin. Neuropharmacol. (1993) 16(5):451-455. (Pubitemid 23292101)
50. EHYAI A, KILROY AW, FENICHEL GM: Dyskinesia and akathisia induced by ethosuximide. Am. J. Dis. Child. (1978) 132(5):527-528.
51. KIRSCHBERG GJ: Dyskinesia: an unusual reaction to ethosuximide. Arch. Neurol. (1975) 32:137-138.
52. DOOLEY J, CAMFIELD P, BUCKLEY D, GORDON K, WIRRELL E, CAMFIELD C: Methsuximide-induced movement disorder. Pediatrics (1991) 88(6):1291-1292.
53. KERRICK JM, KELLEY BJ, MAISTER BH, GRAVES NM, LEPPIK IE: Involuntary movement disorders associated with felbamate. Neurology (1995) 45(1):185-187.
54. REEVES AL, SO EL, SHARBROUGH FW, KRAHN LE: Movement disorders associated with the use of gabapentin. Epilepsia (1996) 37(10):988-990. (Pubitemid 26314960)
55. BUETEFISCH CM, GUTIERREZ A, GUTMANN L: Choreoathetotic movements: a possible side effect of gabapentin. Neurology (1996) 46(3):851-852. (Pubitemid 26099673)
56. JACOB PC, CHAND RP, OMEIMA EL-S: Asterixis induced by gabapentin. Clin. Neuropharmacol. (2000) 23(1):53. (Pubitemid 30090413)
57. HUPPERTZ HJ, FEUERSTEIN TJ, SCHULZE-BONHAGE A: Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia (2001) 42(6):790-792. (Pubitemid 32605944)
58. JONGSMA MJ, LAAN LA, VAN EMDE BOAS W, MEINARDI H: Reversible motor disturbances induced by vigabatrin. Lancet (1991) 338(8771):893.
59. WOLANCZYK T, GRABOWSKA-GRZYB A: Transient dystonias in three patients treated with tiagabine. Epilepsia (2001) 42(7):944-946. (Pubitemid 32783106)
60. FROST MD, RITTER FJ, HOSKIN C, MIMS J, ESPO-LILLO J: Movement disorder associated with lamotrigine treatment in children and adolescents. Epilepsia (1996) 37:112. Abstract.
61. VERMA A, MILLER P, CARWILE ST, HUSAIN AM, RADTKE RA: Lamotrigine-induced blepharospasm. Pharmacotherapy (1999) 19(7):877-880. (Pubitemid 29415844)
62. ROSENBAUM AH, DE LA FUENTE JR: Benzodiazepines and tardive dyskinesia. Lancet (1979) 27:200-201.
63. STOLAREK IH, FORD MJ: Acute dystonia induced by midazolam and abolished by flumazenil. Br. Med. J. (1990) 300:614-615.
64. DULAC O, BONUCCELLI U: Seizures and movement disorders precipitated by drugs. In: Epilepsy and movement disorders. Guerrini R, Aicardi J, Andermann F, Hallett M (Eds), Cambridge University Press (2002).
65. REUTENS DC, DUNCAN JS, PATSALOS PN: Disabling tremor after lamotrigine with sodium valproate. Lancet (1993) 17(342):185-186. (Pubitemid 23200473)
66. EDWARDS KR: Felbamate and tremor. Neurology (1995) 45(10):1951.
67. PERUCCA E: Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs (2002) 16(10):695-714. (Pubitemid 35176854)
68. WATTS RL, KOLLER WC: Movement disorders: Neurologic principles and practice. Watts RL, Koller KC (Eds), McGraw-Hill Professional, New York (1997).
69. SETHI KD, HITRI A, DIAMOND BI: Phenytoin potentiation of neuroleptic-induced dyskinesias. Mov. Disord. (1990) 5(4):325-327. (Pubitemid 20373616)
70. JIMENEZ-JIMENEZ FJ, GARCIA-RUIZ PJ, MOLINA JA: Drug-induced movement disorders. Drug Saf. (1997) 16(3):180-204. (Pubitemid 27145965)
71. BLAKELEY J, JANKOVIC J: Secondary paroxysmal dyskinesias. Mov. Disord. (2002) 17(4):726-734. (Pubitemid 41295012)
72. DHANARAJ M, RADHAKRISHNAN AR, SRINIVAS K, SAYEED ZA: Sodium valproate in Sydenham's chorea. Neurology (1985) 35(1):114-115. (Pubitemid 15193636)
73. HARDOY MC, HARDOY MJ, CARTA MG, CABRAS PL: Gabapentin as a promising treatment for antipsychotic-induced movement disorders in schizoaffective and bipolar patients. J. Affect. Disord. (1999) 54(3):315-317. (Pubitemid 29329442)
74. GENEL F, ARSLANOGLU S, URAN N, SAYLAN B: Sydenham's chorea: clinical findings and comparison of the efficacies of sodium valproate and carbamazepine regimens. Brain Dev. (2002) 24(2):73-76. (Pubitemid 34224906)
75. NUTT GJ: Levodopa-induced dyskinesia: review, observations and speculations. Neurology (1990) 40:340-345.
76. WALDMEIER PC: Is there a common denominator for the antimanic effect of lithium and anticonvulsants? Pharmacopsychiatry (1987) 20:37-47. (Pubitemid 17049357)
77. CHADWICK D, REYNOLDS EH, MARSDEN CD: Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J. Neurol. Neurosurg. Psychiatry (1976) 39(12):1210-1218. (Pubitemid 8022982)
78. CALABRESI P, GIACOMINI P, CENTONZE D, BERNARDI G: Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann. Neurol. (2000) 47(4 Suppl. 1):S60-S68. Discussion S68-S69.
79. LEACH MJ, MARDEN CM, MILLER AA: Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia (1986) 27:490-497. (Pubitemid 16026042)
80. MELDRUM BS: Excitatory amino acid transmitters in epilepsy. Epilepsia (1991) 32:S1-S3.
81. STARR MS, STARR BS, KAUR S: Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease. Neurosci. Biobehav. Rev. (1997) 21:437-446. (Pubitemid 27255848)
82. SHINOTOH H, VINGERHOETS FJ, LEE CS et al.: Lamotrigine trail in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study. Neurology (1997) 48:1282-1285. (Pubitemid 27240549)
83. RICHTER A, LOSCHMANN PA, LOSCHER W: The novel antiepileptic drug, lamotrigine, exerts prodystonic effects in a mutant hamster model of generalized dystonia. Eur. J. Pharmacol. (1994) 3(264):345-351. (Pubitemid 24335476)